Rapid Outbreak


Day Zero Diagnostics introduces the precision and clarity of whole genome sequencing to outbreak investigations with epiXact® (pronounced epi-zact).

  • Sequencing and analysis using single-nucleotide polymorphism (SNP) comparisons of the whole genome.
  • Superior resolution to traditional techniques such as molecular strain typing or PFGE.
  • Definitive determination of pathogen relatedness in less than 2 days.
  • Gives you the confidence to act quickly when an outbreak is real and to call off unnecessary and expensive interventions when an outbreak can be ruled out.

Request an Investigation


Healthcare-associated infections (HAIs) are a widespread challenge for patient care, annually affecting 4% of hospitalized patients in the U.S.1 and resulting in 99,000 patient deaths per year.2

The rising prevalence of multi-drug resistant organisms (MDROs) has made HAIs particularly dangerous, increasing the pressure for rapid, effective interventions when an outbreak is suspected.3,4

Case Studies

Significant Economic Impact

Imprecise and subjective processes that are commonly used today to identify a suspected transmission often drive the implementation of expensive and burdensome cautionary control measures without the benefit of definitive confirmation of an outbreak.

In cases where an outbreak requires an urgent, wide-ranging intervention, a lack of precision and certainty can compromise the speed of the organization’s response.

Failure to control an outbreak can result in patient harm and financial penalties from payors for poor performance.

WGS literature suggests that the rate and spread of HAIs in hospitals is underestimated when compared to routine manual surveillance.

In a recent study, WGS identified 34 clusters in one institution where only one transmission cluster had been suspected by traditional infection control surveillance methods.


Day Zero Diagnostics is your rapid response partner in high stakes situations
Suspected Outbreak

Hospital identifies cluster of isolates in a suspected event (ex: 3 unusual pathogens
with identical antibiograms in the NICU)

Samples Sent to Day Zero


Rapid sequencing AND analysis of isolates

Results Provided Within 1-2 Days in Clear, Easy-to-Understand Report

Rule Out

Avoid Unnecessary Interventions
and Costly Cautionary Measures

Removal of beds, rooms, and equipment
from service

Healthcare worker screening & decolonization

Deep disinfection and cleaning

Inefficient use of staff and resources

Confirmed Outbreak

Drive Effective Organizational Engagement

Clear, definitive results for decision making

Organizational buy-in

Better and more effective interventions

Increased patient care and trust


Contact Us

For more information or to initiate epiXact HAI service, email us at epiXact@dayzerodiagnostics.com or submit a request form and our team will contact you promptly.

Sample Transfer

Our microbiologists will provide you with straightforward sample handling instructions and work with your microbiology lab to obtain your samples quickly and efficiently.

Sequencing and Analysis

Our scientists will prepare your samples and perform deep-coverage whole genome sequencing. Our world class computational biologists will then analyze your genomic data using our custom bioinformatics pipelines.

Report Delivery

Within 1-2 days of receiving your samples, a clear and concise report will be generated and delivered electronically. Our expert analysts will be available for your questions.

Report Details

  • Determination of outbreak cluster inclusion / exclusion for each sample
  • Confirmation of organism ID and Multi-locus Sequence Typing (MLST) typing
  • SNP based sequence analysis and distance matrix visualization of relatedness
  • Sequencing quality metrics including genome coverage and Q-score

HIPAA Seal of Compliance” width=

Request an epiXact Investigation

To contact us immediately, submit a service request below or email us at epiXact@dayzerodiagnostics.com. Our team will contact you promptly.




  1. Magill SS et al. N Engl J Med 2014; 370(13): p. 1198-1208.
  2. Klevens RM et al. Public Health Reports 2007; 122(2): p. 160-166.
  3. Weiner LM et al. MMWR Morb Mortal Wkly Rep 2016; 65(9): p. 235-41.
  4. Neidell MJ et al. Clin Infect Dis 2012; 55(6): p. 807-15.